

**Lanark Laboratories**

NEAR ELECTRICITY SUB DIVISION, GONDPUR, PAONTA SAHIB, DISTT. SIRMOUR-173025, H.P.(INDIA).

**CERTIFICATE OF ANALYSIS (FINISHED PRODUCT)**

(The Drugs &amp; Cosmetics Act 1940 at the under form 39)

Work Order No.: 252612022

Document No.: 252614949

Ref. STS No.	10513	Product Code	FG02367
Product Name	TAB. ROSZE-10 (ZLP) (10X15)		
Generic Name	ROSUVASTATIN TABLETS I.P. 10 MG		
Batch No.	425-429	Date Of Sampling	20/06/2025
Batch Size	2,85,000 TAB	Cumulative Qty.	2,81,220 TAB
		Sample Quantity	60 TAB
Mfg. Date	06/2025	Exp. Date	05/2027
		Quantity Release	2,81,160 TAB
A. R. No.	PL25FG02027	Date Of Release	30/06/2025

S NO.	Tests	Specification	Results
1	Description	An orange colour round shape biconvex film coated tablet, having central break line on one side and plain on other side.	An orange colour round shape biconvex film coated tablet, having central break line on one side and plain on other side.
2	Identification	Should be positive for Rosuvastatin calcium.	Positive.
3	Average weight	224-mg $\pm$ 7.5%	227.16 mg
4	Uniformity of weight	$\pm$ 7.5% of average weight	-0.90%, +2.08%
5	Disintegration Time	NMT 30 Minutes	01 Min 10 Sec
6	Dissolution	Q. Not less than 70.00%	Mean-96.34 %
7	Related substances by HPLC	Complies with I.P.	Complies
8	Uniformity of content	Between 85.00% to 115.00%	87.63% to 102.69%
9	Composition: Each film-coated tablet contains:	Limit	Assay
10	Rosuvastatin Calcium I.P. Eq. to Rosuvastatin 10 mg.	Rosuvastatin Tablets contain not less than 90.0 % and not more than 110.0 % of the stated amount of Rosuvastatin.	101.68 %

**Remarks** The above sample ~~complies~~ does not comply with prescribed standards of Quality with respect to above tests as per IP/BP/USP/in house specification.

Prepared By

Date 30/06/2025

Appendix No.: -

Checked By

Date 30/06/2025

Confidential

QCM  
Approved By

Date 30/06/2025

Page 1 of 1